Incannex Healthcare (NASDAQ: IXHL) restarts share buyback, holding $75M cash and no debt
Rhea-AI Filing Summary
Incannex Healthcare Inc. has reactivated its previously approved share repurchase program and has already bought back shares over the past two trading days. The board decided to restart buybacks because it believes the company’s market value is too low relative to its cash, clinical progress, and future prospects.
Incannex reports approximately $75 million in cash on hand and no debt following recent financing, giving it flexibility to fund development of IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder while repurchasing stock. As of December 31, 2025, about $18.5 million remained available under the repurchase authorization.
The company plans to use the program opportunistically based on market conditions, trading volumes, available capital and broader needs. The buyback authorization does not require any minimum level of repurchases and may be modified, suspended or discontinued at the company’s discretion.
Positive
- None.
Negative
- None.
Insights
Incannex restarts a flexible buyback, signaling confidence but preserving cash.
Incannex Healthcare has reactivated its share repurchase program and has already repurchased stock over the last two trading days. Management frames this as a response to what it views as a disconnect between the company’s balance sheet strength, clinical progress and current market valuation.
The company highlights approximately $75 million in cash and no debt following a recent financing, alongside about $18.5 million remaining available for repurchases as of December 31, 2025. The program is explicitly opportunistic and can be modified, suspended or discontinued, so actual impact depends on future execution, market conditions and ongoing funding needs for IHL-42X, PSX-001 and other candidates.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
Not applicable | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone
Number, including Area Code:
(Former Name or Former Address, if Changed Since Last Report): Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On March 27, 2026, Incannex Healthcare Inc. (the “Company”) issued the press release furnished as Exhibit 99.1.
The information contained in Item 7.01 in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated as of March 27, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Incannex Healthcare Inc. | ||
| Date: March 27, 2026 | /s/ Joel Latham | |
| Name: | Joel Latham | |
| Title: | Chief Executive Officer and President | |
2
Exhibit 99.1
Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position
Board initiates buyback activity following period of inactivity, with repurchases executed over the past two trading days
Melbourne and New York – 27 March – Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has reactivated its previously approved share repurchase program, with the program having been active over the past two trading days.
The Company has utilized the buyback program opportunistically in the past, however had not actively repurchased shares in recent periods. The decision to reinitiate buyback activity reflects the Board of Directors’ view that the Company’s current market valuation does not accurately reflect the strength of its balance sheet, clinical progress, and future potential.
Following its recent financing, Incannex has approximately $75 million in cash on hand and no debt, positioning the Company with significant financial flexibility as it advances its clinical pipeline, including IHL-42X for obstructive sleep apnea and PSX-001 for the treatment of generalized anxiety disorder.
At current trading levels, the Company believes its market capitalization represents a significant disconnect relative to its underlying financial strength and the progress achieved across its clinical programs.
CEO Commentary
“We have taken the decision to reactivate our share buyback program, which has been active over the past two trading days, as we believe the current valuation of the Company does not reflect the strength of our balance sheet or the progress we have made across our clinical pipeline,” said Joel Latham, President and Chief Executive Officer of Incannex Healthcare.
“While we have used the share repurchase program opportunistically in the past, we have not been active in recent periods. The decision to re-engage reflects our conviction in deploying capital in a manner to potentially enhance shareholder value”
“With approximately $75 million in cash and no debt, we are in a strong financial position to execute on our clinical development strategy while maintaining the flexibility to allocate capital in a disciplined and strategic manner. As we progress key milestones across IHL-42X and PSX-001, we believe the Company is well positioned to unlock meaningful value.”
Capital Allocation Strategy
The Company intends to continue to utilize the share buyback program opportunistically, taking into account market conditions, trading volumes, and the Company’s broader capital requirements. As of December 31, 2025, approximately $18.5 million remained available for repurchases under the share repurchase program.
The buyback program does not obligate the Company to acquire any specific number of shares and may be modified, suspended, or discontinued at any time at the Company’s discretion. The timing and amount of any repurchases will depend on market conditions, available capital resources, and other factors.
About Incannex Healthcare Inc.
Incannex is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The Company is advancing three clinical-stage product candidates based on evidence-based innovation and supported by streamlined operations. Incannex's lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnea. In a Phase 2 development program, IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. Approved for Phase 2 clinical development, PSX-001 is an oral synthetic psilocybin treatment for the treatment of generalized anxiety disorder. Incannex's programs target disorders that have limited, inadequate, or no approved pharmaceutical treatment options. For additional information on Incannex, please visit our website at www.incannex.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to management’s expectations regarding the share repurchase program, expectations regarding use of the Company’s cash on hand, the potential value of the Company’s drug candidates and business, including these values as compared to available cash, opportunities, the strategy, timing and future development of the Company’s drug candidates, the potential value of the Company and its drug candidates and potential shareholder value. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company, its operations or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the risk that the Company’s estimates and current projections regarding the sufficiency of its current cash on hand to fund the Company’s planned operations may be incorrect and the Company may use these resources faster than anticipated or suspend the share repurchase program and other risks described in the section entitled "Risk Factors" described in the prospectus supplement and in the Company's annual report on Form 10-K for the fiscal year ended June 30, 2025, filed with the SEC on September 29, 2025, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, which can be obtained on the SEC website at www.sec.gov and are made available on the Company’s website upon their filing with the SEC. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor & Media Contacts
CORE IR
(212) 655-0924
investors@incannex.com
media@incannex.com.au
FAQ
What did Incannex Healthcare (IXHL) announce about its share repurchase program?
How much cash and debt does Incannex Healthcare (IXHL) report in this update?
How large is Incannex Healthcare’s (IXHL) remaining share buyback authorization?
Why is Incannex Healthcare (IXHL) reactivating its buyback program now?
How will Incannex Healthcare (IXHL) decide when to repurchase shares?
Which drug candidates does Incannex Healthcare (IXHL) highlight alongside the buyback?
Filing Exhibits & Attachments
4 documents